Cited 21 time in
Maspin polymorphism associated with apoptosis susceptibility and in vivo tumorigenesis
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Jang, Hye-Lim | - |
| dc.contributor.author | Nam, Eunsook | - |
| dc.contributor.author | Lee, Kon Ho | - |
| dc.contributor.author | Yeom, Seonyong | - |
| dc.contributor.author | Son, Hee Jung | - |
| dc.contributor.author | Park, Chaehwa | - |
| dc.date.accessioned | 2022-12-27T06:05:21Z | - |
| dc.date.available | 2022-12-27T06:05:21Z | - |
| dc.date.issued | 2008-09 | - |
| dc.identifier.issn | 1107-3756 | - |
| dc.identifier.issn | 1791-244X | - |
| dc.identifier.uri | https://scholarworks.gnu.ac.kr/handle/sw.gnu/27288 | - |
| dc.description.abstract | Maspin is a tumor suppressor protein that stimulates apoptosis and inhibits motility, invasion and cancer metastasis. We report on a previously uncharacterized Pro/Ser (C to T) polymorphism at amino acid 176 of the human maspin protein. We analyzed the maspin mutation in 17 cancer cell lines and 36 cancer tissues. Association of polymorphic variants on apoptosis, colony formation and in vivo tumor formation was evaluated. Mutant maspin was found to be frequently expressed in gastric cancer (32/36, 89%). According to predicted maspin tertiary structure, the polymorphic residue is located on the surface of the protein proximal to the reactive site loop domain, and thus may significantly affect the protein interactions of maspin. Stable expression of the Pro and Ser forms of maspin in lung cancer cells revealed that cells expressing Ser176 maspin showed significantly decreased apoptosis and increased colony formation compared with those expressing Pro 176 maspin. In a mouse model, cells expressing Ser176 maspin showed a higher rate of tumor formation in vivo than those harboring Pro176 maspin. Therefore, P176S (C526T) substitution of maspin may result in a partial loss of the tumor suppressor function of this protein, contributing to decreased susceptibility to apoptosis and malignant progression. | - |
| dc.format.extent | 6 | - |
| dc.language | 영어 | - |
| dc.language.iso | ENG | - |
| dc.publisher | SPANDIDOS PUBL LTD | - |
| dc.title | Maspin polymorphism associated with apoptosis susceptibility and in vivo tumorigenesis | - |
| dc.type | Article | - |
| dc.publisher.location | 그리이스 | - |
| dc.identifier.doi | 10.3892/ijmm_00000027 | - |
| dc.identifier.scopusid | 2-s2.0-53049094830 | - |
| dc.identifier.wosid | 000259519400009 | - |
| dc.identifier.bibliographicCitation | INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, v.22, no.3, pp 333 - 338 | - |
| dc.citation.title | INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE | - |
| dc.citation.volume | 22 | - |
| dc.citation.number | 3 | - |
| dc.citation.startPage | 333 | - |
| dc.citation.endPage | 338 | - |
| dc.type.docType | Article | - |
| dc.description.isOpenAccess | Y | - |
| dc.description.journalRegisteredClass | scie | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.relation.journalResearchArea | Research & Experimental Medicine | - |
| dc.relation.journalWebOfScienceCategory | Medicine, Research & Experimental | - |
| dc.subject.keywordPlus | TUMOR-SUPPRESSOR MASPIN | - |
| dc.subject.keywordPlus | CRYSTAL-STRUCTURE | - |
| dc.subject.keywordPlus | PROSTATE-CANCER | - |
| dc.subject.keywordPlus | EXPRESSION | - |
| dc.subject.keywordPlus | MAMMARY | - |
| dc.subject.keywordPlus | SERPIN | - |
| dc.subject.keywordPlus | GENE | - |
| dc.subject.keywordAuthor | maspin | - |
| dc.subject.keywordAuthor | polymorphism | - |
| dc.subject.keywordAuthor | apoptosis | - |
| dc.subject.keywordAuthor | tumorigenesis | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
Gyeongsang National University Central Library, 501, Jinju-daero, Jinju-si, Gyeongsangnam-do, 52828, Republic of Korea+82-55-772-0532
COPYRIGHT 2022 GYEONGSANG NATIONAL UNIVERSITY LIBRARY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
